Characterization of the novel HLA-A*01:367 allele by sequencing-based typing.

HLA-A*01:367 human leukocyte antigen novel allele sequencing-based typing

Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
07 2021
Historique:
received: 06 05 2021
accepted: 09 05 2021
pubmed: 13 5 2021
medline: 8 7 2021
entrez: 12 5 2021
Statut: ppublish

Résumé

HLA-A*01:367 differs from HLA-A*01:01:01:01 by one nucleotide substitution in codon 271 in exon 4.

Identifiants

pubmed: 33979455
doi: 10.1111/tan.14297
doi:

Substances chimiques

Codon 0
HLA-A Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-44

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the ion torrent S5 XL platform. HLA. 2020;95(1):30-39. https://doi.org/10.1111/tan.13708.
Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA database. Nucleic Acids Res. 2020;48:D948-D955. https://doi.org/10.1093/nar/gkz950.
Bouthemy C, Ralazamahaleo M, Jollet I, Filloux M, Visentin J, Guidicelli G. Improvement in HLA-typing by new sequence-specific oligonucleotides kits for HLA-A, -B and -DRB1 loci. HLA. 2018;92(5):279-287. https://doi.org/10.1111/tan.13382.
Teles E, Oliveira DM, Marroquim MSC, de Serpa Brandão RMS, et al. pHLA3D: updating the database of predicted three-dimensional structures of HLA with HLA-DR, HLA-DQ and HLA-DP molecules. Hum Immunol. 2021;82(1):8-10. https://doi.org/10.1016/j.humimm.2020.10.007.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455. https://doi.org/10.1111/j.1399-0039.2010.01466.x.

Auteurs

Marine Cargou (M)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
University of Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France.

Vincent Elsermans (V)

CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France.

Isabelle Top (I)

CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France.

Laura Blouin (L)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

Jonathan Visentin (J)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
University of Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH